Ferric Carboxymaltose (FCM), as a next-generation intravenous iron agent, provides a rapid, safe, and effective solution for patients to replenish their iron stores expeditiously. It has gained widespread application globally and has been endorsed by numerous authoritative guidelines across various disciplines both domestically and internationally. Since its approval for the Chinese market in November 2022, FCM has significantly enhanced the convenience of intravenous iron supplementation for Chinese patients. Capable of delivering a one-time dose of 1000 mg of iron, FCM considerably shortens the treatment duration and improves patient compliance due to its high safety profile, which carries a lower risk of allergic reactions. Furthermore, it reduces hospitalization costs, thereby extending its benefits to a broader patient population.